Seattle Genetics, Inc., a biotechnology company, focuses on the development and commercialization of targeted therapies for the treatment of cancer. ADCETRIS ADCETRIS is an antibody-drug conjugate (ADC) comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE), utilizing proprietary technology. The company began to recognize product sales and cost of sales following the accelerated approval of ADCETRIS by the U.S Food and Drug Administration (FDA) in 2011. The company is in the process of collaborating with Takeda Pharmaceutical Company Limited (Takeda) to develop and commercialize ADCETRIS worldwide. Under this collaboration, the company has retained commercial rights for ADCETRIS in the United States and its territories; and in Canada. ADCETRIS was granted conditional marketing authorization in the European Union in 2012 for patients with relapsed Hodgkin lymphoma or relapsed sALCL. The company and Takeda have received marketing authorizations by regulatory authorities in 39 countries, including Japan, Australia, Switzerland, South Korea and Singapore. Other Programs The company has five clinical-stage ADC programs, which consist of SGN-CD19A, SGN-CD33A, SGN-LIV1A, ASG-22ME, and ASG-15ME. In addition, the company has multiple pre-clinical-stage programs that are being developed as potential candidates for future clinical-stage development. The company also has collaborations for its ADC technology with biotechnology and pharmaceutical companies, including AbbVie Biotechnology Ltd.; Bayer Pharma AG; Celldex Therapeutics, Inc.; Daiichi Sankyo Co., Ltd.; Genentech, Inc.; GlaxoSmithKline LLC; Pfizer, Inc.; PSMA Development Company LLC, a subsidiary of Progenics Pharmaceuticals Inc.; and Takeda; as well as ADC co-development agreements with Agensys, Inc., an affiliate of Astellas Pharma, Inc., Genmab A/S, and Oxford BioTherapeutics Ltd. ADC Technologies ADCETRIS and its pipeline of monoclonal antibody-based product candidates utilize the ADC technology. ADCs are monoclonal antibodies that are linked to cytotoxic or cell-killing agents. The company’s ADCs utilize monoclonal antibodies that internalize within target cells after binding to a specified cell-surface receptor. The company’s ADCs use proprietary auristatins, which are microtubule disrupting agents, or pyrrolobenzodiazepine (PBD), dimers, which are DNA cross-linkers, as cell-killing agents. ADCETRIS, SGN-CD19A, SGN-CD33A, SGN-LIV1A, ASG-22ME, and ASG-15ME all utilize its proprietary, auristatin-based or PBD-based ADC technology. The company also has developed a proprietary sugar enhanced antibody (SEA) technology, which is a process to enhance the effector function of monoclonal antibodies to further increase their antitumor activity by selectively reducing sugars in the monoclonal antibodies, specifically fucose. Strategy The company’s strategy is to become a developer and marketer of targeted therapies for cancer. Main elements of its strategy are as follows: successfully execute ADCETRIS commercial plan; expand the therapeutic potential of ADCETRIS; continue to develop other pipeline programs; continue to leverage industry-leading ADC Technology; support future growth of pipeline through internal research efforts and strategic in-licensing; and enter into strategic product collaborations to generate capital and supplement internal resources. Patents For ADCETRIS and related ADC technology, the company’s 27 issued patents would expire between 2014 and 2026 in the United States and Europe. Of these 27 patents, the company owns rights to 16 patents and has licensed rights to 11 patents. For SGN-CD19A and related ADC technology, the company’s 20 issued patents would expire between 2024 and 2029. For SGN-33A and related ADC technology, the company’s one issued patent would expire in 2030. For SGN-LIV1A and related ADC technology, the company’s 23 issued patents would expire between 2014 and 2026. For ASG-22ME and related ADC technology, the company’s 22 issued patents would expire between 2014 and 2026. For ASG-15ME and related ADC technology, the company’s 21 issued patents would expire between 2014 and 2026. History Seattle Genetics, Inc. was founded in 1997. The company was incorporated in Delaware in 1997.
seattle genetics inc (SGT:Berlin)
21823 30th Drive SE
Bothell, WA 98021
|ARIAD Pharmaceuticals Inc||$6.50 USD||+0.06|
|Genmab A/S||kr442.80 DKK||+1.50|
|Insys Therapeutics Inc||$48.65 USD||-0.86|
|MorphoSys AG||€76.30 EUR||-0.101|
|Pfizer Ltd/India||2,047 INR||-52.40|
|View Industry Companies|
|Price/Cash Flow||NM||Not Meaningful|
Sponsored Financial Commentaries
To contact SEATTLE GENETICS INC, please visit www.seattlegenetics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.